Renal disease in the inner city

Seminars in Nephrology

Volumn 21, Issue 4, 2001, Pages 334-345

  Bakir, Asad A ^a,b   Dunea, George ^a,b  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMEGALY; DIALYSIS; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; KIDNEY DISEASE; KIDNEY FAILURE; NEPHROSCLEROSIS; PRIORITY JOURNAL; REVIEW; URBAN AREA;

EID: 0034958553     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.23690     Document Type: Review

References (92)

1. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients
2. Predicting death from renal failure in primary hypertension
3. Uremia from benign nephrosclerosis
4. Uremia from benign nephrosclerosis
5. Etiology of ESRD in the inner city
6. Hypertension-induced end stage renal disease in African Americans
7. Clinical documentation of end-stage renal disease due to hypertension
8. Causes of end-stage renal failure in black patients starting renal replacement therapy
9. Causes of end-stage renal failure
10. The clinical diagnosis of hypertensive nephrosclerosis-how reliable is it?
11. Renal biopsy findings in presumed hypertensive nephrosclerosis
12. Insuffisance renale au cours de l'hypertension arterielle en Afrique noire
13. Marked proteinuria in hypertensive nephrosclerosis
14. Proteinuria in benign nephrosclerosis
15. Proteinuria in hypertension
16. Renal biopsy findings in hypertensive patients with proteinuria
17. Glomerular hyperfiltration indicates early target organ damage in essential hypertension
18. Hypertension-induced renal injury: Is mechanically mediated interstitial inflammation involved?
19. The link between hypertension and nephrosclerosis
20. Treatment of severe hypertension with minoxidil
21. Recovery from renal failure in patients with accelerated hypertension
22. Transient and sustained recovery from renal shutdown in accelerated hypertension
23. Role of cocaine in end stage renal disease in some hypertensive African Americans
24. Drugs of abuse and renal disease
25. The impact of substance abuse on hypertensive end-stage renal disease in inner city African-Americans
26. Prevalence of hypertension in chronic cocaine users
27. Role of nitric oxide in cocaine-induced acute hypertension
28. Cocaine induced hypertension: Role of the peripheral sympathetic system
29. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis
30. Focal segmental glomerulosclerosis: A common entity in nephrotic black adults
31. Racial differences in the prevalence and presentation of glomerular disease in adults
32. Focal segmental glomerulosclerosis in adult African Americans
33. Focal glomerular sclerosis: Contrasting clinical patterns in children and adults
34. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulo-interstitial changes
35. Management of focal segmental glomerulosclerosis: Evidence-based recommendations
36. Focal segmental glomerulosclerosis in adults. Presentation, course, and response to treatment
37. The prognosis of focal segmental glomerulosclerosis of adulthood
38. Favorable prognostic indicators of focal glomerulosclerosis (FSGS). Serum C3 levels and immunosuppressive treatment
39. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children
40. Predictors of progression in collapsing focal segmental glomerulosclerosis (C-FSGS)
41. Collapsing glomerulopathy: A clinically and pathologically distinct variant of focal segmental glomerulosclerosis
42. Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow up study
43. Disappearance of uremia due to heroin associated nephropathy
44. The many masks of focal segmental glomerulosclerosis
45. Changing indicence of glomerular disease in adults
46. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children
47. Natural history of heroin-induced nephropathy
48. Glomerular lesions in the acquired immunodeficiency syndrome
49. Riboflavine and severe lactic acidosis
50. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy
51. Protease inhibitor therapy for HIV infection: The effect on HIV-associated nephrotic syndrome
52. Renal involvement in disorders of connective tissues
53. A multi-center study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis
54. The prognosis of lupus nephritis in African Americans: A retrospective analysis
55. Predicting renal outcome in severe lupus nephritis: Contributions of clinical and histologic data
56. Controlled trial of pulse methyl prednisone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
57. Study of prognostic factors in severe lupus nephritis
58. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients
59. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
60. Clinical features of systemic lupus erythematosus
61. Systemic lupus erythematosus: A review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets
62. Ethnic differences in the symptoms and prognosis of systemic lupus erythematosus. A controlled study in 3 populations
63. DNA analysis of HLA-Dr and Dq genes in American blacks with systemic lupus erythematosus
64. Clinical manifestations of systemic lupus erythematosus: Identification of racial and socioeconomic influences
65. Morbidity of systemic lupus erythematosus: Role of race and socio-economic status
66. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race and thrombocytopenia, as well as causes of death
67. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature
68. The relationship of socioeconomic status to subsequent health status in systemic lupus erythematosus
69. Activation of blood clotting in patients with systemic lupus erythematosus. Relationship to disease activity
70. Immunological findings, thrombocytopenia and disease activity in lupus nephritis
71. Prognostic factors in diffuse proliferative lupus glomerulonephritis
72. Lupus nephritis. Prognostic factors and probability of maintaining life supporting renal function 10 years after the diagnosis
73. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study
74. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia
75. Prognosis of the nephrotic syndrome in sickle glomerulopathy
76. Pathology of the glomerulus in sickle cell anemia with and without nephrotic syndrome
77. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality
78. Renal transplantation in end-stage sickle nephropathy
79. Renal transplantation in patients with sickle cell nephropathy
80. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin converting enzyme
81. Pathophysiology of progressive nephropathies
82. Recovery from acute renal failure after eleven months of hemodialysis
83. Fibrinous pericarditis in hepatorenal failure
84. Acute renal failure in hepatitis A
85. Bromate intoxication: Hairdresser's anuria
86. Large doses of intravenous calcitriol in patients with severe hyperparathyroidism
87. Dialysis-associated renal cystic disease resembling autosomal dominant polycystic kidney disease
88. Family history of end-stage renal disease among incident dialysis patient
89. Life expectancy benefits of cancer screening in the end-stage renal disease population